Which has grown faster, CTSO or KPTI?

Over the past five years, KPTI grew revenue faster — CTSO at a -3.17% CAGR versus KPTI at 7.47%.

How have CTSO and KPTI total returns compared?

Over the past 10 years, CTSO delivered -28.72% and KPTI delivered -41.85% annualized total return. Past performance doesn't predict future results.

Cytosorbents Corporation (CTSO) vs Karyopharm Therapeutics Inc. (KPTI)

A side-by-side comparison of Cytosorbents Corporation and Karyopharm Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CTSO

Cytosorbents Corporation

$13M

$4.01HealthcareDelayed quote: Oct 6, 2026, 11:46 AM EDT

KPTI

Karyopharm Therapeutics Inc.

$15M

$0.67HealthcareDelayed quote: Oct 6, 2026, 12:10 PM EDT

Total return — CTSO vs KPTI

growth of $100 · dividends reinvested · last 10y

CTSO -97.1% (-29.7%/yr)KPTI -99.5% (-41.6%/yr)CTSO compounded faster over this window

Log scale — wide-divergence pair

CTSO KPTI

CTSO vs KPTI: by the numbers

•KPTI is the larger company ($15M vs $13M market cap).
•Both run net losses; CTSO's is the smaller (-48.94% vs -153.28% net margin).
•KPTI grew revenue faster over the past five years (7.47% vs -3.17% CAGR).

Metrics side by side

Valuation

Metric	CTSO	KPTI
P/S ratio	0.34	0.10

Profitability

Metric	CTSO	KPTI
Gross margin	71.61%	95.88%
Operating margin	-33.37%	-56.17%
Net margin	-48.94%	-153.28%
ROIC	-43.31%	N/A

Growth (annualized)

Metric	CTSO	KPTI
Revenue CAGR (5Y)	-3.17%	7.47%
Total return CAGR (5Y)	-52.26%	-62.18%

Frequently asked

Which has grown faster, CTSO or KPTI?: Over the past five years, KPTI grew revenue faster — CTSO at a -3.17% CAGR versus KPTI at 7.47%.
How have CTSO and KPTI total returns compared?: Over the past 10 years, CTSO delivered -28.72% and KPTI delivered -41.85% annualized total return. Past performance doesn't predict future results.

Go deeper

Full CTSO analysis Full KPTI analysis Interactive comparison tool

Dig into the metrics

Cytosorbents ROE Karyopharm Therapeutics ROE Cytosorbents operating margin Karyopharm Therapeutics operating margin Cytosorbents revenue growth Karyopharm Therapeutics revenue growth Cytosorbents free cash flow Karyopharm Therapeutics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.